Hyderabad, Feb 10 (TNT): In a significant push to strengthen translational biomedical research, Syngene International on Tuesday said it has entered into an strategic research collaboration with Johns Hopkins University to advance early-stage drug discovery programs originating from university laboratories.
The partnership focuses on accelerating the transition of fundamental academic research into validated therapeutic candidates, a release said.
Central to the collaboration is Syngene’s SynVent™ platform, which integrates discovery biology, medicinal and synthetic chemistry, DMPK (drug metabolism and pharmacokinetics), toxicology, and early development capabilities designed to de-risk nascent scientific ideas and generate robust preclinical data.
By combining Johns Hopkins’ strengths in basic and applied biomedical research with Syngene’s industrial drug discovery expertise, the collaboration seeks to bridge a long-standing gap between laboratory discoveries and clinically relevant drug programs.
The initiative will also employ Syngene’s Connector model to align promising research with pharmaceutical partners and investors, enabling sustained funding and structured pathways for further development.
Kenneth Barr, Senior Vice President and Head of Strategic Collaborations at Syngene International, said the partnership is aimed at compressing the time taken for high-potential academic discoveries to mature into credible development programs.
He emphasized that integrating early research with end-to-end discovery capabilities can significantly improve translational outcomes.
Paul Nkansah, Senior Director of Corporate Partnerships at Johns Hopkins Technology Ventures, said the collaboration offers a new framework for advancing university-led discoveries.
According to him, the model can connect innovative research from Johns Hopkins laboratories with global drug discovery infrastructure, increasing the likelihood that promising science progresses beyond proof-of-concept toward real-world therapeutic impact.
TNT TS
Leave a Reply